Abstract
The most attractive targets in cancer research include telomere territory and cancer stem cells (CSCs). Both paradigms reflect an interactive manner, involvement of genes and functions. Telomeres have the key role in genetic instability, cell cycle regulation, and cellular senescence. By focusing on the signaling cascade and cell cycle regulation in normal cells and cancer cells, interaction between telomere, telomerase in stem cells seems to be rather complicated. This could predict the fate of cellular proliferation. By considering aging, the timing and speed are the key elements for telomere shortening, and ever-lasting proliferative capacity of cancer stem cells. In embryonic stem cells (ESCs), telomerase is activated and maintains telomere length and cellular immortality. While the telomere and telomerase findings are promising, the genomic reprogramming cells using induced pluripotent stem (iPS) cells in regenerative medicine is extremely vital. This chapter will give an update on current knowledge of telomere function and telomerase activity in stem cells during cancer formation. A network of ‘telomere-telomerase- cancer stem cells’ may translate the required facts for a fundamental cancer drug development in future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akiyoshi T, Nakamura M, Koga K, Nakashima H, Yao T, Tsuneyoshi M, Tanaka M, Katano M (2006) Gli1, down regulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. Gut 55:991–999
Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23:7274–7282
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988
Allan AL, Vantyghem SA, Tuck AB, Chambers AF (2007) Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis 26:87–98
Allsopp RC, Morin GB, DePinho R, Harley CB, Weissman IL (2003) Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102:517–520
Aoudjit F, Vuori K (2001) Integrin signaling inhibits paclitaxelinduced apoptosis in breast cancer cells. Oncogene 20:4995–5004
Armanios M, Greider CW (2005) Telomerase and cancer stem cells. Cold Spring Harb Symp Quant Biol 70:205–208
Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, et al (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. New Engl J Med 356:1317–1326
Armstrong L, Saretzki G, Peters H, Wappler I, Evans J, Hole N, von Zglinicki T, Lako M (2005) Overexpression of telomerase confers growth advantage, stress resistance and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells 23:516–529
Bapat SA (2007) Evolution of cancer stem cells. Semin Cancer Biol 17:204–213
Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65:10783-10793
Begus-Nahrmann Y et al (2009) P53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nat Genet 41:1138–1143
Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622
Bollmann FM (2008). The many faces of telomerase: emerging extratelomeric effects. Bioessays 30:728–732
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
Brennan SK, Wang Q, Tressler R, Harley C, Go N, et al (2010) Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE 5(9):e12487. doi:10.1371/journal.pone.0012487
Chin SE, Artandi Q, Shen A et al (1999) P53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97:527–538
Clarke MF, Fuller M (2006) Stem cells and cancer: two faces of eve. Cell 124:1111–1115
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland MJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951
Cooke HJ, Smith BA (1986). Variability at the telomeres of the human X/Y pseudoautosomal region. Cold Spring Harb Symp Quant Biol 51:213–219
Diévart A, Beaulieu N, Jolicoeur P (1999) “Involvement of Notch1 in the development of mouse mammary tumors”. Oncogene 18(44):5973–5981
Discovery (2011) Overactive breast cancer genes. J Clin Invest (www.ivanhoe.com)
Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS (2004) Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells. Brest Cancer Research 6:R605–R615
Ferron SR, Marques-Torrejon MA, Mira H et al (2009) Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis J. Neurosci 29:14394–14407
Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10:R25
Flores MA, Blasco A (2009) p53-dependent response limits epidermal stem cell functionality and organismal size in mice with short telomeres. PLoS ONE 4:4934
Galli, R. et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011–7021
Gibbs CP et al (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967–976
Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088
Haik S, Gauthier LR, Granotier C, Peyrin JM, Lages CS, Dormont D, Boussin FD (2000) Fibroblast growth factor 2 up regulates telomerase activity in neural precursor cells. Oncogene 19:2957–2966
Harrington L (2004) Does the reservoir for self-renewal stem from the ends? Oncogene 23:7283–7289
Haupt Y, Bath ML, Harris AW, Adams JM (1993) “bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis”. Oncogene 8:3161–3164
Hemmati HD Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183
Herrera E, Samper E, Martín-Caballero J, Flores JM, Lee HW, Blasco MA (1999) Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 18:2950–2960
Hiyama E, Hiyama K (2007) Telomere and telomerase in stem cells. British j cancer 96:1020–1024
Hiyama E, Hiyama K, Tatsumoto N, Kodama T, Shay JW, Yokoyama T (1996) Telomerase activity in human intestine. Int J Oncol 9:453–458
Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA et al (1995) Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 155:3711–3715
Horiguchi K, Toi M, Horiguchi SI, Sugimoto M, Naito Y, Hayashi Y, Ueno T, et al (2010) Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci 57:165–175
Hough MR, Rosten PM, Sexton TL, Kay R, Humphries RK (1994) Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics 22:154–161 (http://www.genomeweb.com/problem-cd24 http://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44. http://www.ncbi.nlm.nih.gov/gene/934)
Ignatova TN et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193–206
Joseph I, Tressler R, Bassett E, Harley C, Buseman CM et al (2010) The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 70:9494–9504
Jothy S (2003) CD44 and its partners in metastasis. Clin Exp Metastas 20:195–201
Kim H, Kim M Ahn S, Son B, Kim S, Jung K, et al (2009) Do stem cell markers have significant implication in breast cancer? Immunohistochemical study for CD44 and CD24. Cancer Research 69(2) (Supplement 1 Abstract nr 5058)
Kim HJ, Kim MJ, Ahn SH, Son BH, Kim SB, Ahn JH, Noh WC, Gong G (2011) Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20:78–85
Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M (2003a) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9:4906–4913
Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I (2003b) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88:231–236
Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone MG, Zaffaroni N, Bilsland A, Keith WN (2009) A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene 28:3765–3774
Lapidot T, Sirard C, Vormoor J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648
Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chunget I Y, et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. British J Cancer 104:1730–1738
Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA (1998) Essential role of mouse telomerase in highly proliferative organs. Nature 392:569–574
Levings PP et al(2009) Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69, 5648–5655
Liu L, DiGirolamo CM, Navarro PA, Blasco MA, Keefe DL (2004) Telomerase deficiency impairs differentiation of mesenchymal stem cells. Exp Cell Res 294:1–8
Lü XQ, Suo Z, Ma CL, Xu KJ, Liu YS, Li HX (2009) Quantity and distribution of CD44+ /CD24− cells in breast cancer tissue and the cell lines 38:441–444
Ma T, Nolan KF, Walsh LA, Tone Y, Thompson SAJ, Waldmann H (1999) Structure and chromosomal location of mouse and human CD52 genes. Biochimica et Biophysica Acta 1446:334–340
Marhaba R, Zöller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211–231
Mason PJ, Wilson DB, Bessler M (2005) Dyskeratosis congenita—a disease of dysfunctional telomere maintenance. Curr Mol Med 5:159–170
McEachern MJ, Krauskopf A, Blackburn EH (2000) Telomeres and their control. Annu Rev Genet 34:331–358
Meirelles Lda S, Nardi NB.(2003) Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br J Haematol 123:702–711
Merlo LMF, Maley CC (2010) The role of genetic diversity in cancer. J Clin Invest 120:401–403
Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425:962–967
Morrison SJ, Prowse KR, Ho P, Weissman IL (1996) Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 5:207–216
Nagano O, Saya H (2004) Mechanism and biological significance of CD44 cleavage. Cancer Sci 95:930–935
Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cell and intrinsic subtypes: contraversis rage on. Curr Stem Cell Res Ther 4:50–60
Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the malignant process. Adv Cancer Res 71:241–319
Naor D, Nedvetzki S, MelnikIG L, Faitelson Y (2002) CD44 in cancer. Clin Lab Sci 39:527–579
National Institutes of Health (2012) U.S. department of health and human services. Available at http://stemcells.nih.gov/info/basics/basics10.2012
Norman ES, RA DePinho (2004) Telomeres stem cells, senescence, and cancer. J Clin Invest 113:160–168
Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680–687
Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302–305
Park SY, Gönen M, Kim HJ, Michor F, Polyak K (2010) Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Inves 120:636–644
Pathak S, Multani AS, Furlong CL, Sohn SH (2002) Telomere dynamics, aneuploidy, stem cells, and cancer. Int J Oncol 20:637–641
Patrawala L, Calhoun T, Schneider-Broussard R, et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696–1708
Polyak K, Weinberg R A (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273
Prockop DJ (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71–74
Reid R, Muslimani A, Downing L, Wills SM, Fennell T, Marples B, Decker D, et al (2010) Expression of CD24 and CD44 tumor cells in breast cancer patients who received neoadjuvant therapy. J Clin Oncol 28 (Suppl; Abstract e21051)
Rudolph KL Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, DePinho RA (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96:701–712
Sagiv E, Arber N (2008) The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepato 2:125–33
Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138:822–829
Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, et al (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22:1410
She M, Chen X (2009) Targeting signal pathways active in cancer stem cells to overcome drug resistance. Chin J Lung Cancer 12:3–7
Sheridan C, H Kishimoto, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet Jr R, Badve S, Nakshatri H (2006) CD44+ /CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research 8:R59
Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, Pflumio F, Junier MP, Chneiweiss H, Boussin FD (2011) Alternative lengthening of telomeres in human glioma stem cells. Stem cell 29:440–451
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
Suer S, Nechiporchik N, Burger A (2011) Targeting the self-renewal capacity of cancer stem cells with the telomere eradicating agent KML001. 2011 world stem cell summit. The Pasadena Convention Center, Pasadena, CA. Poster #: 12
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15:4234–4241
Thomson T, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS et al (1998) Blastocysts embryonic stem cell lines derived from human. Science 282:1145–1147
Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB (1993) Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 52:661–667
Vilborg A, Bersani C, Wilhelm MT, Wiman KG (2011) The p53 target Wig-1: A regulator of mRNA stability and stem cell fate? Cell Death Differ 18:1434–1440
Wang KH, Kao AP, Chang CC, Lee JN, Chai CY, Hou MF, Liu CM and Tsai EM (2010) Modulation of tumorigenesis and oestrogen receptor-α expression by cell culture conditions in a stem cell-derived breast epithelial cell line. Biology of the Cell 102:159–172
Wong KK Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, Alt FW, DePinho RA (2003) Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 421:643–648
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+ /CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Research 10:R10 (http://breast-cancer research.com/content/10/1/R10)
Wright WE, Shay JW (2005) Telomere biology in aging and cancer. J Am Geriatr Soc 53:S292–S294
Yin H, Glass J (2011) The phenotypic radiation resistance of CD44+/CD24− or low breast cancer Cells Is mediated through the enhanced activation of ATM signaling. PLoS ONE 6:e24080. doi:10.1371/journal.pone.0024080
Ying NJ, Chambers I, Smith A (2003) BMP induction of Id proteins Suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 115:281–292
Yu, J et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920
Zglinicki T, Lako M (2005) Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells 23:516–529
Zhang J, Ju Z (2010) Telomere, DNA damage, and oxidative stress in stem cell aging. Birth Defects Res C Embry Today 90:297–307
Zwaka JA, Thompson T(2010). Homologous recombination in human embryonic stem cells. Nature Biotechnology 21: 319–32
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mehdipour, P., Parsa, N. (2013). Cancer Stem Cells. In: Mehdipour, P. (eds) Telomere Territory and Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4632-9_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-4632-9_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4631-2
Online ISBN: 978-94-007-4632-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)